Azurity’s Konvomep Receives the US FDA’s Approval for the Treatment of Active Benign Gastric Ulcer
Shots:
- The US FDA has approved Konvomep (omeprazole and sodium bicarbonate for oral suspension) for the treatment of active benign gastric. The therapy is also indicated for lowering the upper gastrointestinal bleeding risk in critically ill patients
- Konvomep is expected to be commercially available in Q1’23 & may give patients who have difficulty swallowing pills or capsules. Konvomep contains omeprazole (2mg), a proton pump inhibitor, and sodium bicarbonate per mL (84mg)
- The product is available in 90/150/300mL bottles. In July 2022, Azurity’s Zonisade has been approved in the US for partial seizures in adults and pediatric epilepsy patients aged ≥16yrs.
Ref: PR Newswire | Image: Azurity
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
